3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
OTHER
3
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Plasma cell
1
Conditions
Rectal Neoplasms
2
Colorectal Neoplasms
2
Breast Neoplasms
2
Stomach Neoplasms
1
Sarcoma
1
Recurrence
1
Neoplasms
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Colonic Neoplasms
1
Interventions
Dexamethasone
64
Lenalidomide
34
pomalidomide
33
Cyclophosphamide
33
Rituximab
31
Bortezomib
29
venetoclax
27
fludarabine
26
Gemcitabine
21
carfilzomib
20
Paclitaxel
19
pembrolizumab
17
daratumumab
16
Cisplatin
16
Carboplatin
15
Calcium Dobesilate
14
Azacitidine
14
ibrutinib
12
Docetaxel
12
Cytarabine
12
obinutuzumab
11
Nivolumab
11
durvalumab
10
Doxorubicin
10
Bevacizumab
10
selinexor
9
cemiplimab
9
blinatumomab
9
Injections
9
Cetuximab
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Recurrence
×
Immunoconjugates
×
Clear all
NCT03489525
2022-03-28
MEDI2228
MedImmune LLC
Phase 1
Completed
107 enrolled